Brief: Spago Nanomedical Q2 Sales at SEK 114 Thousand
31/07/2023 08:04
Jul 31 (Reuters) - Spago Nanomedical Q2 net income SEK -7.866 million. * Q2 adjusted EPS SEK -0.09 * Q2 sales SEK 114 thousand * Q2 operating expenses SEK -10.982 million
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose